ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0865

Z’s and Knees: Associations of Participant-reported and Objective Sleep Measures with Pain Among US Veterans with Osteoarthritis of the Knee

David Azizi1, Sarah Wetzel1, Marianna Olave1, Rachel Gillcrist2, Hannah Brubeck3, Daniel White4, Carla Scanzello5, Tuhina Neogi6, Alexis Ogdie7, Bryant England8, Mercedes Quinones9, Katherine Wysham10 and Joshua Baker11, 1Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, 2Corporal Michael J. Crescenz VA Medical Center, Philadelphia, 3VA Puget Sound Health Care System, Seattle, WA, 4University of Delaware, Newark, DE, 5University of Pennsylvania, Philadelphia, PA, 6Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 7Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 8University of Nebraska Medical Center, Omaha, NE, 9Washington DC VA Medical Center, Bethesda, MD, 10VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 11Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA

Meeting: ACR Convergence 2024

Keywords: mental health, Osteoarthritis, pain, physical activity, sleep

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Abstracts: Osteoarthritis – Novel Insights from Observational Studies

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Inadequate sleep is associated with a range of poor health outcomes, including chronic health conditions, mood disorders, and all-cause mortality. There is some evidence that sleep-related problems contribute to chronic pain disorders, but the relationship between sleep and pain remains poorly defined, particularly among patients with knee osteoarthritis (KOA). To our knowledge, prior studies have not evaluated the association between patient-reported and objective sleep measures with pain among people with KOA.

Methods: We evaluated baseline data from 206 Veterans with KOA in a clinical trial designed to examine the effect of physical activity incentives and corticosteroid injections on patient-reported pain and function. During a pre-randomization enrollment period, sleep was measured using the validated patient-reported Pittsburgh Sleep Quality Index (PSQI) and objective sleep duration by wrist activity monitors (Fitbit). PSQI scores above 5 and average total sleep time (TST) less than 7 hours were considered ‘inadequate’ based on prior definitions. Self-reported knee pain and objectively measured regional pain sensitivity were assessed with the Knee Injury and Osteoarthritis Outcome Score (KOOS) and pain pressure threshold testing (PPT) on the participant-identified worse knee, respectively. KOA severity was measured by the Kellgren-Lawrence (KL) grading system. We used linear regression to model the unadjusted and adjusted relationship between sleep measures and pain outcomes. We also explored other predictors of patient-reported pain and pain sensitization in models adjusted for age, gender, race, anxiety, and average daily step count.

Results: Inadequate sleep was common; 164 (80%) and 160 (78%) met criteria by subjective and objective assessments, respectively. Agreement between subjective and objective sleep was poor (κ 0.01). Individuals with inadequate sleep by PSQI were younger and more likely to have anxiety and depression and had significantly worse PPT at the knee. Those identifying as Black or another race were more likely than White individuals to have inadequate objective sleep by TST, as were those with fibromyalgia, higher average step counts, and higher KOOS (Table 1).
In adjusted models, participant-reported sleep was significantly associated with pain sensitivity (PPT) and pain severity (KOOS pain), while objective sleep was not associated with either measure (Figure 1). The diagnosis of anxiety significantly increased KOOS pain but not PPT. Both were ameliorated by age (Figure 2). 

Conclusion: Most participants had inadequate sleep by both participant-reported and objective measures, illustrating extent of poor sleep among Veterans with KOA. The report of poor sleep, but not objective assessments of inadequate sleep duration, was associated with worse pain and worse regional pain sensitivity. These observations suggest that perception of poor sleep is more relevant to how patients with KOA experience pain. Anxiety and depression were associated with poorer sleep and were the largest contributors to worse self-reported pain. Further research should elucidate additional mediators and potential interventions for patients with KOA who report poorer sleep. 

Supporting image 1

Figure 1: Pain measures (KOOS pain on left; pain sensitivity at knee on right) in patients with inadequate sleep duration by Fitbit and inadequate sleep by self-report, adjusting for age, sex, race, average steps per day, and a diagnosis of anxiety.

Supporting image 2

Figure 2: Standardized differences in pain sensitivity at the knee and self-reported pain (KOOS pain) by clinical characteristic (standardized regression coefficients).

Supporting image 3

Table 1: Characteristics of patients with adequate and inadequate sleep as defined by self-report and Fitbit objective assessments.


Disclosures: D. Azizi: None; S. Wetzel: None; M. Olave: None; R. Gillcrist: None; H. Brubeck: None; D. White: None; C. Scanzello: None; T. Neogi: Amgen, 2, Eli Lilly, 2, GlaxoSmithKlein(GSK), 2, Novartis, 2, Sobi, 2; A. Ogdie: AbbVie, 2, 5, Amgen, 2, 5, Bristol Myers Squibb, 2, Celgene, 2, CorEvitas, LLC, 2, Eli Lilly and Company, 2, Gilead, 2, GSK, 2, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Takeda, 2, UCB Pharma, 2; B. England: Boehringer-Ingelheim, 5; M. Quinones: CVS Caremark, 2, Pfizer, 5; K. Wysham: None; J. Baker: CorEvitas, LLC, 2, Cumberland Pharma, 2, Formation Bio, 2, Horizon, 5.

To cite this abstract in AMA style:

Azizi D, Wetzel S, Olave M, Gillcrist R, Brubeck H, White D, Scanzello C, Neogi T, Ogdie A, England B, Quinones M, Wysham K, Baker J. Z’s and Knees: Associations of Participant-reported and Objective Sleep Measures with Pain Among US Veterans with Osteoarthritis of the Knee [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/zs-and-knees-associations-of-participant-reported-and-objective-sleep-measures-with-pain-among-us-veterans-with-osteoarthritis-of-the-knee/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/zs-and-knees-associations-of-participant-reported-and-objective-sleep-measures-with-pain-among-us-veterans-with-osteoarthritis-of-the-knee/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology